LOOP DIURETICS IN HEART FAILURE: EVIDENCE-BASED CHOICE

Wiad Lek. 2021;74(4):1003-1006.

Abstract

Objective: The aim: Of the article is to conduct a comparative evaluation of the effectiveness of torasemide and furosemide in patients with heart failure.

Patients and methods: Materials and methods: Analysis of the existing clinical trials and meta-analyzes that combine the results of the completed studies aimed at the investigation of comparative efficacy of furosemide and torasemide in patients with heart failure (НF).

Conclusion: Conclusions: There is enough convincing evidence to speak about the advantages of torasemide over furosemide both in terms of its pharmacological properties and taking into account the reduction of hospitalizations, functional progress and improvement in the quality of life of patients with НF. The safety profile of torasemide is more favorable, as it is associated with a reduced risk of hypokalemia compared to furosemide. The abovementioned facts favor the use of torasemide in patients with symptomatic НF, as well as the transition from furosemide to torasemide in patients with edema caused by НF, which remain uncontrolled despite receiving optimal doses of furosemide.

Keywords: furosemide; heart failure; torasemide.

MeSH terms

  • Diuretics / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Quality of Life
  • Sodium Potassium Chloride Symporter Inhibitors* / therapeutic use
  • Sulfonamides / therapeutic use
  • Torsemide

Substances

  • Diuretics
  • Sodium Potassium Chloride Symporter Inhibitors
  • Sulfonamides
  • Torsemide